1 Tabriz University of Medical Sciences, School of Medicine, Tabriz, East Asarbeidjan, Iran ; 2 Department of Radiation, School of Paramedicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran ; 3 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Cancer Biol Med. 2014 Jun;11(2):78-85. doi: 10.7497/j.issn.2095-3941.2014.02.002.
Esophageal cancer has been reported as the ninth most common malignancy and ranks as the sixth most frequent cause of death worldwide. Esophageal cancer treatment involves surgery, chemotherapy, radiation therapy, or combination therapy. Novel strategies are needed to boost the oncologic outcome. Recent advances in the molecular biology of esophageal cancer have documented the role of genetic alterations in tumorigenesis. Oncogenes serve a pivotal function in tumorigenesis. Targeted therapies are directed at the unique molecular signature of cancer cells for enhanced efficacy with low toxicity. RNA interference (RNAi) technology is a powerful tool for silencing endogenous or exogenous genes in mammalian cells. Related results have shown that targeting oncogenes with siRNAs, specifically the mRNA, effectively reduces tumor cell proliferation and induces apoptotic cell death. This article will briefly review studies on silencing tumor enhancer genes related to the induction of esophageal cancer.
食管癌已被报道为第九大常见恶性肿瘤，位居全球第六大死亡原因。食管癌的治疗方法包括手术、化疗、放疗或联合治疗。需要新的策略来提高肿瘤学的结果。食管癌分子生物学的最新进展记录了遗传改变在肿瘤发生中的作用。癌基因在肿瘤发生中起着关键作用。靶向治疗针对癌细胞的独特分子特征，以提高疗效和降低毒性。RNA 干扰 (RNAi) 技术是在哺乳动物细胞中沉默内源性或外源性基因的有效工具。相关结果表明，用 siRNA 靶向癌基因，特别是 mRNA，可有效抑制肿瘤细胞增殖并诱导细胞凋亡。本文将简要回顾与诱导食管癌相关的肿瘤增强子基因沉默的研究。
